Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F7 | P08709 | 8/20 | 0.38 |
| ▸ | F3 | P13726 | 8/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 5/20 | 0.36 |
| ▸ | F2 | P00734 | 3/20 | 0.36 |
| ▸ | F10 | P00742 | 3/20 | 0.36 |
| ▸ | F11 | P03951 | 3/20 | 0.36 |
| ▸ | TACR3 | P29371 | 1/20 | 0.35 |
| ▸ | SYK | P43405 | 1/20 | 0.34 |
| ▸ | AURKA | O14965 | 1/20 | 0.34 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.33 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2914505 | 0.92 | F7 (0.42) | F7F3ROCK2F2F10 | |
| SCHEMBL2854787 | 0.92 | F7 (0.39) | F7F3F2F10F11 | |
| SCHEMBL2853690 | 0.91 | F7 (0.38) | F7F3POLBROCK2F2 | |
| SCHEMBL2854584 | 0.90 | F7 (0.39) | F7F3F2F10F11 | |
| SCHEMBL2853524 | 0.88 | F7 (0.41) | F7F3F2F10F11 | |
| SCHEMBL2855265 | 0.88 | F7 (0.41) | F7F3F2F10F11 | |
| SCHEMBL2853036 | 0.86 | RPS6KB1 (0.36) | POLBROCK2SYKAURKARPS6KB1 | |
| SCHEMBL2850797 | 0.86 | F7 (0.37) | F7F3F2F10F11 | |
| SCHEMBL2848623 | 0.86 | F7 (0.35) | F7F3F2F10F11 | |
| SCHEMBL4657711 | 0.86 | F7 (0.46) | F7F3F2F10F11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1910298-B1 | PHENYLGLYCINAMIDE AND PYRIDYLGLYCINAMIDE DERIVATIVES USEFUL AS ANTICOAGULANTS | BRISTOL MYERS SQUIBB CO (US) | 2010-01-13 | — | — | EP | disclosed |
| US-7456195-B2 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-11-25 | — | — | US | disclosed |
| US-20070003539-A1 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070003539-A1 | Phenylglycinamide and pyridylglycinamide derivatives useful as anticoagulants | F12, F11, F7 | F7 3/4885F3 10/4885POLB 2996/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.